Company / Accounts Receivable
Beta Bionics, Inc. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$17.1M
FY2025
5-year range
$4.4M / $17.1M
FY2023-FY2025
Trend
+42.7%
vs FY2024
Sector context
#129 of 138
Health Care
What the data says
Among 138 Health Care companies, Beta Bionics, Inc. is in the bottom 7% for accounts receivable. Improved from $4M to $17M over the past 2 years.
Based on SEC 10-K filings.
$17M in FY2025.
Improved from $4M to $17M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 138This company $17.1M Sector average $1.3B
▼
-98.7% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 42.7% year-over-year.
- Ranks #129 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.1M | +42.7% |
| FY2024 | $12.0M | +169.7% |
| FY2023 | $4.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026